ArticleArthritis research & therapy2026
Reversing detrimental effects of OA-related terminal maturation in high-throughput in vitro and biomimetic ex vivo human models.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundOsteoarthritis (OA) lacks disease-modifying therapies, in part due to limited human-relevant preclinical models. OA pathophysiology is characterized by loss of chondrocyte maturation arrest, producing growth plate-like changes and terminal differentiation. We aimed to establish a scalable human organoid-based platform for efficient therapeutic screening.
methodsCartilage organoids were derived from OA patient tissues in a 96-well format and benchmarked against matched osteochondral explants. Terminal maturation was induced using triiodothyronine (T3). Three candidate compounds, all thyroid hormone receptor blockers, were tested across dose ranges and incubation times. The most effective compound was validated in a human biomimetic osteochondral explant model to assess translational relevance.
resultsThe high-throughput organoid platform consistently reproduced hypertrophic responses, closely mirroring osteochondral explant behavior, and provided reliable readouts of terminal maturation marker CCDC80, Of the three compounds evaluated, Compound A demonstrated the strongest effects, significantly increasing CCDC80 mRNA and MMP3 protein levels in the organoid system. In the osteochondral explant model, Compound A reversed T3-induced terminal maturation, suppressing markers including CCDC80, PHOSPHO1, and MMP3.
conclusionThis study introduces a scalable and reproducible preclinical screening strategy using human OA tissues for compound evaluation. The platform enables efficient dose-response testing and identifies thyroid signaling as a promising therapeutic axis for modulating chondrocyte maturation. These findings suggest a novel approach to slow OA progression, preserve joint function, and improve mobility and quality of life in affected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.